Familial chylomicronemia syndrome (FCS)- Refile NDA for Volanesorsen (WAYLIVRA) with USFDA in H2 2020

Volanesorsen (WAYLIVRA) is the leading drug in Familial chylomicronemia syndrome (FCS) space globally., developed by Ionis & Akcea Therapeutics. Familial chylomicronemia syndrome (FCS) is a rare autosomal recessive disease caused by mutations in the lipoprotein […]